SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immucell (ICCC) - Potential Treatment for Cryptosporidium
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ed who wrote (19)6/10/1997 8:09:00 AM
From: Jonathan Rothschild   of 46
 
No predictions on the stock price. However,IMHO, much of the selling has been cleaned up. The stock has a checkered history from the early days when it was a penny stock undergoing a 100 to 1 reverse split. That's why there are so many 100 share blocks hanging around. No market maker wants to touch a stock in which he's hit constantly for 100 x 2 1/2. The ticket charge exceeds their profit.There are only wholesale market makers in this stock who know nothing of the company's prospects. This scenario creates an ideal buying opportunity. This is a company with great fundamentals and has problems unrelated to its core business. The problem with this stock, as the company admits, is a lack of sponsorship. However, this is going to change soon. The products and studies which will be released soon could have broad public appeal. 1)Lactoferrin is a safe, immunomodulating agent, derived from cow's milk that will be picked up by the health food industry for immediate sales. 2) Cryptoscan is a water diagnostic which will go on sale shortly to water utility districts. According to reports by water quality experts, it is the most sensitive and accurate test for crytosporridium parvum in municipal water supplies. This is the same organism that caused many deaths in Milwaukee. The EPA has recently adminished New York City for not conducting tests on their Croton surface water reservoir. All you need is a drought this summer for the story to hit the major newspapers. 3) Results of phase II Diffgam study, a product designed to treat hospital based colitis (major market) will be released some time this summer. This study was outsourced. 4) Results from major phase II field trial with Travelgam (Traveller's Diarrhea) will be released before the end of the year. This study is conducted by the navy who will be responsoble for patient accrual. The fact that the Navy is willing to conduct such a study, using its own resources, is an accomplishment in itself.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News